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Resuscitation with polymeric plasma 
substitutes is permissive for systemic 
inflammatory response syndrome and sepsis 
in multiply injured patients: a retrospective 
cohort study
Kai Sprengel1, Hanspeter Simmen1, Clément M. L. Werner1, Simon Sulser2, Michael Plecko1,  
Catharina Keller3 and Ladislav Mica1* 
Abstract 
Objective: Multiple trauma is often accompanied by systemic inflammatory response syndrome (SIRS). The aim of 
this study was to investigate the impact of polymeric plasma substitutes on the development of SIRS or sepsis.
Methods: We included 2969 patients aged ≥16 years with an Injury Severity Score (ISS) >16 in this study. The sample 
was subdivided into three groups: patients who did not receive colloids and those who received <5L colloids and >5L 
colloids within the first 48 h. Data were analyzed using IBM SPSS® for Windows version 22.0; analysis of variance was 
used for continuous normally distributed data and Kruskal–Wallis test for categorical data. The predictive quality of 
colloid treatment was analyzed using the receiver operating characteristic (ROC) curves. Independent predictively 
was analyzed by binary logistic regression. Data were considered significant if P < 0.05. Data are presented as the 
mean ± standard deviation.
Results: The SIRS score increased with the amount of colloid used (1.9 ± 1.4 vs. 2.4 ± 1.2 vs. 3.2 ± 0.9; P < 0.001). 
However, the predictive quality was low, with an area under the ROC of 0.693 for SIRS and 0.669 for sepsis (P < 0.001). 
Binary logistic regression revealed colloids as an independent factor for the development of SIRS and sepsis (odds 
ratios: SIRS 3.325 and sepsis 8.984; P < 0.001).
Conclusion: Besides other factors, colloids have a significant permissive effect and are independent predictors for 
the development of SIRS and sepsis in multiply injured patients.
Trial registration ‘Retrospektive Analysen in der Chirurgischen Intensivmedizin’ No. St. V. 01-2008
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Background
The most frequent cause of death in the young and pro-
ductive adult population is trauma. Bleeding, surgery, 
and coagulopathy are the main killers of severely injured 
patients [1, 2]. The more severely a patient is injured, the 
more they tend to bleed and develop systemic inflam-
matory response syndrome (SIRS) [3]. Besides emer-
gency surgical interventions, efficient infusion therapy in 
severely injured patients is the key method of improving 
the survival of patients. According to Advanced Trauma 
Life Support (ATLS) guidelines, the initial volume ther-
apy should be administered in a balanced way with fur-
ther ongoing saline or transfusion therapy according to 
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the patient’s physiological state with a permissive hypo-
tension. The symptoms of SIRS in severe injury resemble 
a systemic disease. During the last decade, hydroxyethyl 
starch derivates (HES) and other colloids have been 
extensively postulated as therapeutic agents to prevent 
capillary leakage during SIRS and to influence blood 
coagulation [4–6]. Overactivation of the immune system 
during SIRS leads to its depression through the compen-
satory anti-inflammatory response syndrome (CARS). 
In this phase, multiply injured patients are highly sus-
ceptible to infections, which increase their mortal-
ity and hospitalization. Positive immunomodulation 
by an appropriate infusion therapy in multiply injured 
patients could be very useful for improving the survival 
and outcome of these patients. Hospitalization could be 
shortened, leading to a decrease in treatment costs. The 
colloids included in this study are both HES and modified 
gelatin. The absence of clear infusion protocols for colloi-
dal plasma expanders may lead to involuntary mixtures 
of infused colloids. In this retrospective cohort study, we 
asked how colloids influence the development of SIRS 
and sepsis in patients with multiple traumas, apart from 
other factors with a significant permissive effect on the 
development of SIRS and sepsis.
Methods
Patient sample
In this retrospective cohort study, we included 2969 
patients with severe injuries admitted to the trauma bay 
of the University Hospital of Zürich (Switzerland) during 
the period 1996–2011. The data from 120 patients were 
incomplete and excluded from this study. The inclusion 
criteria were an Injury Severity Score (ISS) >16 points, 
age  ≥16  years, and admission within at least 24  h of 
incurring the severe injury. The patient sample was sub-
divided into three groups (Table 1) according to the use 
or otherwise of colloids. All patient data were collected 
retrospectively. The observation period was 30  days 
maximally or until the discharge of the patient. The data 
were retrieved from patient records with the approval of 
the local institutional review board (IRB) according to 
the University of Zürich IRB guidelines and the World 
Medical Association Declaration of Helsinki. The study 
was conducted according to our institutional guidelines 
for good clinical practice (Ethics Committee of the Uni-
versity Hospital of Zürich Permission: ‘Retrospektive 
Analysen in der Chirurgischen Intensivmedizin’ No. St. V. 
01-2008). No individual consent was required. The data 
were not age or sex matched.
Diagnostic protocol
Unstable patients underwent resuscitative procedures 
according to the ATLS guidelines of the American 
College of Surgeons. Hemodynamically stable patients 
received diagnoses according to clinical findings or 
whole-body computed tomography (CT) in uncertain 
situations. Hemodynamically unstable patients received 
focus-oriented diagnostics with immediate problem solv-
ing according to the ATLS guidelines.
Primary care
The treatment of all patients admitted was according to 
the ATLS guidelines and the previously assessed trauma 
management protocol, after appropriate indications had 
been identified [7, 8].
Scoring systems
The overall physiological impairment was evaluated from 
the Acute Physiology and Chronic Health Evaluation 
(APACHE II) score of the patient at admission [9]. The 
ISS and the New Injury Severity Scale (NISS) were used 
to define the severity of trauma [10, 11]. The Abbreviated 
Injury Scale (AIS; 2005 version) was used to describe 
injuries in specific anatomical regions.
Laboratory parameters
Blood lactate levels, pH, and hematocrits were measured 
at intervals using a blood gas analyzer (ABL800 Flex, 
Radiometer, Thalwil, Switzerland). The prothrombin time 
was measured using a standardized method [12].
Transfusion resuscitation of multiply injured patients
Infusion and transfusion therapies for multiply injured 
patients were applied according to damage control resus-
citation criteria [13] and the guidelines of the University 
Hospital of Zurich [14].
Plasma substitutes
The only plasma substitutes (colloids) used were Physi-
ogel balanced (succinylated gelatin, 23.2 [kDa], B. Braun 
Medical, Sempach, Switzerland), Voluven (hydroxyethyl 
starch 130/0.4) 6 % (Fresenius Kabi, Bad Homburg, Ger-
many), and Tetraspan (hydroxyethyl starch 130/0.4) 6 % 
(B. Braun Medical).
Assessment of SIRS and sepsis
The worst values for leukocyte count, respiratory rate, 
heart rate, and temperature were taken to determine the 
SIRS score each day [15]. SIRS was measured during the 
first 30  days after admission or as long as the patients 
were hospitalized. Sepsis was defined as an SIRS score 
≥2 with an infectious focus.
Statistical analysis
Data are presented as the mean ± standard deviation for 
continuous variables and as percentages for categorical 
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variables. Cases with an incomplete data set were dis-
carded from this study (n  =  52). Two-tailed Kolmogo-
rov–Smirnov tests were used for testing normality and, 
if P < 0.05, the data were considered to be normally dis-
tributed. The data for the groups were compared using a 
χ2 test and a Kruskal–Wallis test for categorical data and 
one-way analysis of variance (ANOVA) for continuous 
data. If a Kolmogorov–Smirnov test showed P  >  0.05, 
Mann–Whitney non-parametric U test was used for 
continuous data. Results were considered significant 
if P  <  0.05. The predictive quality for SIRS and sepsis 
of colloids was reported as the area under the receiver 
operator characteristic (ROC) curve. The entire amount 
of infused colloids was used as a predictor for SIRS and 
sepsis. Odds ratios (ORs) were calculated for categorical 
data. Independent predictivity was analyzed using binary 
logistic regression with the Hosmer–Lemeshow test for 
the goodness of fit; good if P > 0.05. Data were analyzed 
using IBM SPSS Statistics for Windows software (version 
22.0; IBM Corp., Armonk, NY, USA).
Results
Patient sample
The group of patients not receiving colloids was sig-
nificantly larger than the group that received col-
loids  <5L/48  h and  >5L/48  h (1659 vs. 858 vs. 452, 
P  <  0.001). There were significantly more male 
than female patients in all three groups (P  <  0.001) 
(Table  1). The patients who did not receive colloids 
were significantly older than those who received 
colloids  <5L/48  h and  >5L/48  h [46.9  ±  20.1 vs. 
43.7  ±  19.2 vs. 37.4  ±  16.3 (a); P  <  0.001; Table  1]. 
Patients receiving colloids  >5L/48  h were significantly 
more severely injured. Interestingly, patients receiv-
ing colloids <5L/48 h had the lowest trauma load (ISS: 
28.1 ± 14.5 vs. 26.8 ± 13.4 vs. 33.8 ± 13.4, P < 0.001; 
NISS: 38.5  ±  17.8 vs. 34.6  ±  15.1 vs. 44.1  ±  15.1; 
P  <  0.001; Table  1). The lactate levels [3.3  ±  2.9 vs. 
2.7  ±  2.0 vs. 3.1  ±  2.3 (mmol/L); P  <  0.001; Table  1] 
and base excess [–3.9 ± 6.1 vs. –3.3 ± 4.3 vs. –4.9 ± 4.6 
(m  Eq/L); P  <  0.001; Table  1] were significantly 
Table 1 The characteristics of  the patient sample at  admission for  those not receiving colloids vs. receiving col-
loids <5L/48 h vs. colloids >5L/48 h
The precise injury pattern and the baseline physiological parameters at admission are shown. GCS Glasgow Coma Scale, FFP fresh frozen plasma
* ANOVA
† Kruskal–Wallis
‡ χ2 Significant if P < 0.05
At admission No colloids Colloids <5L/48 h Colloids >5L/48 h P value
Age (a) 46.9 ± 20.1 43.7 ± 19.2 37.4 ± 16.3 <0.001*
Gender (male/female) 1211/448 618/240 357/95 <0.001‡
AIS head 3.0 ± 2.0 2.5 ± 2.0 3.2 ± 1.9 <0.001*
AIS face 0.5 ± 1.0 0.6 ± 1.1 0.7 ± 1.1 <0.001†
AIS thorax 1.5 ± 1.7 1.7 ± 1.7 2.0 ± 1.7 <0.001*
AIS abdomen 1.0 ± 1.7 1.0 ± 1.6 1.4 ± 1.9 <0.001†
AIS spine 0.7 ± 1.3 0.9 ± 1.4 0.9 ± 1.5 <0.001†
AIS extremities 1.2 ± 1.4 1.5 ± 1.5 1.8 ± 1.5 <0.001*
AIS pelvis 0.5 ± 1.1 0.6 ± 1.2 0.7 ± 1.3 0.010†
AIS soft tissue 0.4 ± 0.8 0.6 ± 0.8 0.6 ± 0.8 <0.001†
ISS 28.1 ± 14.5 26.8 ± 13.4 33.8 ± 13.4 <0.001*
NISS 38.5 ± 17.8 34.6 ± 15.1 44.1 ± 15.1 <0.001*
GCS 8.5 ± 5.5 9.8 ± 5.3 6.7 ± 5.1 <0.001*
Base excess (mEq/L) −3.9 ± 6.2 −3.3 ± 4.3 −4.9 ± 4.6 <0.001*
Lactate (mmol/L) 3.3 ± 2.9 2.7 ± 2.0 3.1 ± 2.3 <0.001*
Hematocrit (%) 33.3 ± 9.0 34.6 ± 7.4 31.8 ± 8.4 <0.001*
Hemoglobin (g/dL) 11.3 ± 4.7 11.6 ± 2.5 10.7 ± 3.0 <0.001*
Prothrombin time (%) 77.7 ± 23.5 82.0 ± 19.7 75.5 ± 21.8 <0.001*
Leukocytes (103/μL) 17.8 ± 5.6 13.4 ± 5.8 13.2 ± 5.9 0.025†
APACHE II 15.5 ± 9.8 12.6 ± 7.2 16.8 ± 7.4 <0.001*
Erythrocytes (U) 15.0 ± 15.0 0.8 ± 2.5 4.9 ± 10.6 <0.001*
Platelets (U) 0.6 ± 3.6 1.6 ± 5.4 9.7 ± 21.1 <0.001*
FFP (U) 0.7 ± 4.0 2.8 ± 7.2 12.5 ± 15.9 <0.001*
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elevated in patients from the group who received col-
loids  >5L/48  h compared with the levels and base 
excess in patients from the group not receiving colloids 
and those in the group receiving colloids <5L/48 h. Cal-
culation of the APACHE II score showed similar results 
(15.5  ±  9.8 vs. 12.6  ±  7.2 vs. 16.8  ±  7.4; P  <  0.001; 
Table 1); the value was significantly elevated in patients 
from the group who received colloids  >5L/48  h com-
pared with that in patients from the group not receiv-
ing colloids and those from the group receiving 
colloids <5L/48 h.
Analysis of SIRS, infection, and sepsis
The SIRS score at admission was significantly elevated in 
patients from the groups receiving colloids (2.1 ± 1.2 vs. 
2.2 ± 1.1 vs. 2.6 ± 1.1; P < 0.001; Table 2). An increase 
over time in the SIRS score was observed in these 
patients (1.9 ± 1.4 vs. 2.4 ± 1.2 vs. 3.2 ± 0.9; P < 0.001; 
Table 2); however, a maximum was reached more slowly 
in patients from the group receiving colloids [2.2 ±  3.6 
vs. 3.1 ± 4.4 vs. 5.9 ± 5.7 (d); P < 0.001; Table 2]. The rates 
of sepsis increased according to increasing colloid use (10 
vs. 16 vs. 36 %; P < 0.001; Table 2). However, the onset of 
sepsis was later according to the use of colloids [7.9 ± 7.1 
vs. 6.4 ± 5.4 vs. 9.1 ± 5.7 (d); P < 0.001; Table 2].
Binary logistic regression revealed the application of 
colloids to be an independent factor in the development 
of SIRS (Wald: 174.229; OR 3.325; P < 0.001) and sepsis 
(Wald: 108.989; OR 8.984; P < 0.001). However, EC, TC, 
and FFP revealed SIRS and sepsis to be an independent 
predictors for multiply injured patients (Table 3A). Inter-
estingly, the onset was earliest in patients from the group 
receiving colloids  <5L/48  h. ROC analysis showed the 
highest predictive power for SIRS (AUC 0.69; P < 0.001, 
CI 95  %, 0.653, 0.733; OR 3.33), followed by sepsis 
(AUC 0.669; P  <  0.001; CI 95  %, 0.637, 0.706; OR 2.72) 
(Table 3B.).
Outcome of the patient sample
Interestingly, the overall mortality was significantly lower 
in the colloid-treated groups (40 vs. 12 vs. 20 %; P < 0.001; 
Table  4A) than in the group not treated with colloids. 
The hospitalization time [13.4 ± 19.5 vs. 19.7 ± 14.7 vs. 
28.0 ± 22.5 (d); P < 0.001; Table 5A], intensive care unit 
(ICU) stay [5.9  ±  9.0 vs. 8.9  ±  9.4 vs. 18.3  ±  13.1 (d); 
P  <  0.001; Table  5A], and ventilator-assisted ICU treat-
ment [3.5 ± 6.8 vs. 5.3 ± 7.4 vs. 13.1 ± 10.4 (d); P < 0.001; 
Table  4A] were significantly increased in patients from 
the groups treated with colloids. However, patients 
treated with colloids that eventually died survived longer 
than those who were not treated with colloids [1.9 ± 4.4 
vs. 6.7 ± 9.2 vs. 12.7 ± 15.0 (d); P < 0.001; Table 4A]. In 
the binary logistic regression, polymeric plasma sub-
stitutes only influenced the time spent in the hospital 
(Wald: 7.205; OR 0.767; P = 0.007; Table 4B), the number 
of respirator-associated days in the ICU (Wald: 5.065; OR 
1.154; P = 0.024; Table 4B), and the time of death (Wald: 
8.039; OR 1.142; P = 0.005; Table 4B). The application of 
colloids in multiply injured patients is not an independ-
ent predictor of death, as shown by the binary logistic 
regression (Wald: 0.000; OR 1.000; P = 1.000; Table 4B).
Analysis of co‑founding factors of SIRS and sepsis
The analysis revealed that in both groups, SIRS and sep-
sis, the GCS, base excess, and lactate played a significant 
permissive role for the development of SISR and sep-
sis in multiply injured patients (Table 5). The AIS spine, 
extremities, and pelvis as well as the prothrombin time, 
leukocyte counts, and APACHE II score had a significant 
effect on the development of SIRS and sepsis (Table 5.).
Discussion
There is no doubt that polymeric saccharides such as 
HES can effectively expand blood volume and improve 
survival in patients with multiple injuries. The analysis 
Table 2 The development of SIRS and sepsis in the patient sample
Patients not receiving colloids vs. receiving colloids <5L/48h vs. colloids >5L/48h are compared. The sequence of SIRS development, sepsis, and the onset of sepsis 
and septic shock are shown in the investigated patient sample
* ANOVA
‡ Kruskal–Wallis
Significant if P < 0.05
No colloids Colloids <5L/48h Colloids >5L/48h P value
SIRS admission 2.1 ± 1.2 2.2 ± 1.1 2.6 ± 1.1 <0.001‡
SIRS maximum 1.9 ± 1.4 2.4 ± 1.2 3.2 ± 0.9 <0.001*
SIRS day of maximum 2.2 ± 3.6 3.1 ± 4.4 5.9 ± 5.7 <0.001*
Sepsis (% of each group) 10 16 36 <0.001‡
Day of sepsis onset 7.9 ± 7.1 6.4 ± 5.4 9.1 ± 5.7 <0.001‡
Septic shock (% of each group) 3 2 9 <0.001‡
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submitted to the US Food and Drug Authority in the 
early 1970s would not be considered adequate to detect 
the possible side effects of HES in the present day. Since 
then, an increasing number of publications with concerns 
about HES, but with only partially selective outcome 
reporting (only positive outcomes) have been published 
Table 3 (A) The binary logistic regression analysis of the patient sample revealed that the infusion of colloids within the 
first 48  h after  trauma is an independent predictor for  the development of  SIRS and  sepsis. Hosmer–Lemeshow test, 
P < 0.001 for SIRS and P < 0.001 for sepsis. (B) ROC curve of the patient sample
AUC area under the curve, FFP fresh frozen plasma
Significant if P < 0.05
Binary logistic regression Wald Odds P value
(A) The binary logistic regression analysis of the patient sample
SIRS (colloids) 174.229 3.325 <0.001
Sepsis (colloids) 108.989 8.984 <0.001
SIRS (EC) 39.242 1.955 <0.001
Sepsis (EC) 69.910 1.848 <0.001
SIRS (platelets) 6.303 0.972 0.012
Sepsis (platelets) 0.005 0.998 0.944
SIRS (FFP) 4.335 0.942 0.037
Sepsis (FFP) 10.447 1.217 0.001
ROC AUC P value
(B) Predictive quality depicted by AUC of the corresponding ROC
SIRS (colloids) 0.693 <0.001
Sepsis (colloids) 0.669 <0.001
SIRS (EC) 0.539 <0.001
Sepsis (EC) 0.821 <0.001
SIRS (platelets) 0.501 <0.001
Sepsis (platelets) 0.677 <0.001
SIRS (FFP) 0.512 <0.001
Sepsis (FFP) 0.807 <0.001
Table 4 The outcome (A) of the patient sample with its binary logistic regression (B) to detect colloids as an independent 
factor for an adverse outcome under severe injury conditions
* ANOVA
† Kruskal–Wallis
Significant if P < 0.05
Outcome No colloids Colloids <5L/48h Colloids >5L/48h P value
(A) The outcome of the patient sample
Hospitalization (d) 13.4 ± 19.5 19.7 ± 14.7 28.0 ± 22.5 <0.001*
ICU (d) 5.9 ± 9.0 8.9 ± 9.4 18.3 ± 13.1 <0.001*
Respirator (d) 3.5 ± 6.8 5.3 ± 7.4 13.1 ± 10.4 <0.001*
Death [d] 1.9 ± 4.4 6.7 ± 9.2 12.7 ± 15.0 <0.001*
Death (% of each group) 40 12 20 <0.001†
Outcome binary logistic regression Wald Odds P value
(B) Independent outcome parameters of colloid application
Hospitalization (d) 7.205 0.767 0.007
ICU (d) 3.560 1.233 0.059
Respirator (d) 5.065 1.154 0.024
Death (d) 8.039 1.142 0.005
Death (% of each group) 0.000 1.000 1.000
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[16–19]. In this retrospective cohort study, the focus was 
set on the application of polymeric plasma substitutes in 
the context of severe injury. Therefore, the question was 
asked how these substances influence the immunity sys-
tem in multiple trauma patients. Patients who received 
more polymeric plasma substitute suffered significantly 
more severe SIRS and sepsis. Certainly, there are a lot of 
confounders for the development of SIRS and sepsis in 
multiply injured patients, but one key factor is the use of 
polymeric plasma substitutes, as supported by the highly 
significant binary logistic regression analysis (Table  3). 
Therefore, in this study, it may be concluded that besides 
other factors, polymeric plasma substitutes contrib-
ute significantly to the development of SIRS in multiply 
injured patients. However, the impact of injury severity 
on the development of SIRS and sepsis also plays a piv-
otal role [3]. Overactivation of the immune cells for the 
clearance of destroyed tissue might be the reason. The 
products used in this study vary over almost two decades; 
however, the one thing they all have in common is that 
they are all polymers. Polymeric substances might have 
pharmacologic effects on the reticulo-endothelial system 
(RES). There is growing evidence that polymeric plasma 
substitutes may inhibit the RES by inhibition of cytokine 
secretion [20]. The question of whether polymeric plasma 
expanders influence the RES was asked in the late 1980s. 
The application of HES reduced the phagocytic activity 
of RES; however, the data were unclear and lacked robust 
statistical analysis [21, 22]. Therefore, a partial immu-
nosuppressive effect for polymeric plasma substitutes 
must be postulated. This seems to be reflected in the ORs 
obtained by the binary logistic regression, 3.325 for SIRS 
and 8.984 for sepsis (Table 3). Certainly, a higher trauma 
load in the patient sample receiving more polymeric 
plasma substitutes is obtained; therefore the trauma 
load and other factors also contribute to the develop-
ment of SIRS and sepsis [3], which is indirectly reflected 
by the small AUC. How brain injury is involved in both 
SIRS and sepsis development remains speculative. The 
impaired blood–brain barrier under trauma conditions 
may release microglial cytokines to influence the immune 
system systemically. At this time, little is known about 
the influence of sugar polymers on immune physiology 
in humans; however, these data show that indications 
for their use in patients with multiple traumas should 
be clarified. The mixed outcomes might also be partly 
caused by the higher ISS at admission, but the polymeric 
plasma substitutes also seem to have a significant influ-
ence on pulmonary function in multiple trauma patients, 
as reflected by the ventilator-associated days in the ICU, 
the hospitalization duration, and the time of death, some-
how in a paradox manner (Table 4). Interestingly, in this 
Table 5 Possible co-founding factors of SIRS and sepsis
Significant results are highlighted in italics. Hosmer–Lemeshow P = 0.001 fors SIRS and P = 0.2 for sepsis
SIRS Sepsis
Wald Odds P value Wald Odds P value
Age (a) 0.423 0.998 0.515 7.968 0.991 0.005
Gender (male/female) 0.000 0.998 0.987 0.252 1.065 0.616
AIS head 0.006 0.996 0.936 1.130 1.045 0.288
AIS face 0.096 1.020 0.757 0.695 1.043 0.405
AIS thorax 0.028 0.992 0.867 1.292 1.044 0.256
AIS abdomen 0.044 0.990 0.833 0.525 1.028 0.469
AIS spine 7.822 1.149 0.005 2.587 1.064 0.108
AIS extremities 9.302 1.171 0.002 23.463 1.220 <0.001
AIS pelvis 8.782 1.211 0.003 2.823 0.924 0.093
AIS soft tissue 0.008 0.993 0.930 2.961 1.118 0.085
ISS 0.067 1.003 0.795 0.071 1.002 0.790
NISS 3.112 1.012 0.078 0.601 0.996 0.438
GCS 20.401 0.907 <0.001 7.397 0.954 0.007
Base excess (m Eq/L) 5.449 0.956 0.020 30.932 0.907 <0.001
Lactate (mmol/L) 4.136 0.928 0.042 15.893 0.879 <0.001
Hematocrite (%) 1.230 0.971 0.267 0.007 1.002 0.934
Hemoglobin (g/dL) 0.455 1.055 0.500 0.029 0.988 0.864
Prothrombin time (%) 0.777 1.003 0.378 4.785 1.006 0.029
Leukocytes (103/μL) 7.267 1.034 0.007 3.344 1.018 0.067
APACHE II 1.091 0.984 0.296 10.359 0.959 0.001
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patient sample, the mortality was significantly lower in 
the group receiving colloids >5L/48 h. The ISS, APACHE 
II, and all other parameters except for age were signifi-
cantly higher at admission for this patient group. Age 
was <40 years (37.4 ± 16.3 [a]). Whether such a signifi-
cant break point for multiply injured patients occurs at 
about the age of 40  years remains speculative; however, 
age appears to play a pivotal role in the pathophysiology 
of multiply injured patients.
Limitations
A limitation, and a possible source of bias, is the chang-
ing fluid resuscitation protocols over the study period, 
which could make the interpretation less reliable. The 
chosen selection criteria might counteract this bias.
Conclusions
Polymeric plasma substitutes should be applied to mul-
tiply injured patients in a more tailored fashion, because 
besides many other factors these plasma substitutes 
might permissively affect SIRS and sepsis. However, 
patient survival might be positively influenced by the 
application of polymeric plasma substitutes, as depicted 
in this sample.
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